Figure 3 | British Journal of Cancer

Figure 3

From: Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials

Figure 3

Cytoplasmic SPARC expression as a potential negative predictive biomarker for overall survival ( A and C ) and progression-free survival ( B and D ) in gemcitabine-treated aPDAC patients. Univariate analysis (Kaplan–Meier curves and log-rank tests) of cytoplasmic SPARC expression in the tumour tissue of (A and B) gemcitabine-based treated aPDAC pts and (C and D) fluoropyrimidine-based treated aPDAC pts. Crossed lines indicate censored cases.

Back to article page